Wu described an allogeneic type of HSCT known as ‘haploidentical’, or derived from half-matched donor, such as a parent or child. Data from 2019 showed that in China, haploidentical HSCT ...

The study "demonstrated that outcomes after [haploidentical stem cell transplant] in patients with severe thalassemia are ...

Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

However, allogeneic stem cell transplant required ... All of these were integrated into a new system for haploidentical HSCT, named the ‘Beijing Protocol’ by Worldwide Network for Blood ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

NK cells, as opposed to T cells, do not induce graft-versus-host disease (GVHD), therefore treatment-related toxicity owing to allogeneic ... after T-cell-depleted haploidentical hematopoietic ...

Researchers sought to determine whether venetoclax plus decitabine would lead to enhanced feasibility for allogeneic HSCT in patients with AML.

MSCs are isolated from the bone marrow of healthy adult human donors and are used to treat SR-aGVHD in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).